Nivolumab in Patients With Recurrent Malignant Mesothelioma
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, phase II trial in previously treated patients with MPM who
are considered candidates for immunotherapy and repeat thoracoscopies/transthoracic biopsies.
Nivolumab will be administered 3 mg/kg q2 weeks by intravenous injection.
The administration of nivolumab as monotherapy will improve DCR form 20% to 40% at 12 weeks
when compared to DCR of patients treated with best supportive care based on historical
controls.